Brien, Rita
Volpe, Isabelle
Grigg, Jasmin
Lyons, Tom
Hughes, Caitlin
McKinnon, Ginny
Tzanetis, Stephanie
Crawford, Sione
Eade, Alan
Lee, Nicole
Barratt, Monica J.
Funding for this research was provided by:
National Centre for Clinical Research on Emerging Drugs
Article History
Received: 23 March 2022
Accepted: 24 February 2023
First Online: 9 March 2023
Change Date: 25 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12954-023-00783-0
Declarations
:
: Ethical approval for the project was granted by the RMIT College Human Ethics Advisory Network on 18 December 2019 (22591-11/19). Survey and workshop participants were provided explanatory statements about research objectives, process, and intention to publish results prior to data collection.
: Consent during survey and feedback sessions was implied by completion/participation. Intention to publish aggregate findings was made explicitly clear, and participants were provided access to the explanatory statement. Informed consent was recorded digitally for virtual workshop via an approved electronic Participant Information Sheet/Consent Form, which included explicit consent for researchers to report deidentified data and findings.
: IV, RB, GM, and MJB are volunteers for The Loop Australia (TLA), a health promotion charity working towards delivering drug-checking services in Australia that repackages and shares drug alert information with its networks. NL also sits on the board of TLA. ST is an employee of CanTEST Health and Drug Checking Service, a fixed-site drug-checking service delivered by Directions Health Services in partnership with CAHMA and Pill Testing Australia, funded by ACT Health. MJB also serves as the Executive Director of Bluelight.org, which hosts digital harm reduction communities where alerts about unusual drugs are often shared.